A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors - NCT06257264

Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Part 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-68501, Part 1: Recommended dose(s) for Expansion (RDFE) of BG-68501 in participants with solid tumors, (and 13 more...)